ESPR Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Esperion Therapeutics Inc

Watchlist Manager

Watchlist

Price: 3.18 USD Market Closed

Market Cap: $819.5m

	Esperion Therapeutics Inc NASDAQ:ESPR	US
	AZ-Com Maruwa Holdings Inc F:1YM	JP
A	Ameren Corp DUS:AE4	US
	Davide Campari Milano NV MIL:CPR	IT
	Coca Cola HBC AG LSE:CCH	CH
L	Lam Research Corp SWB:LAR	US
N	Network18 Media & Investments Ltd NSE:NETWORK18	IN
N	Nucor Corp DUS:NUO	US
K	KeyCorp DUS:KEY	US
C	Commerzbank AG DUS:CBK	DE
S	Sicily By Car SpA F:5LC	IT
K	Koninklijke Philips NV DUS:PHI1	NL

Profitability Summary

Esperion Therapeutics Inc's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

68%

Strong 3Y Average Gross Margin

70%

Gross Margin is Increasing

67% > 68%

Healthy Operating Margin

18%

Negative 3Y Average Operating Margin

-28%

Operating Margin is Increasing

-193% > 18%

Negative Net Margin

-2%

Negative 3Y Average Net Margin

-58%

Net Margin is Increasing

-253% > -2%

Negative Free Cash Flow Margin

-4%

Negative 3Y Average Free Cash Flow Margin

-37%

Free Cash Flow Margin is Increasing

-187% > -4%

Low ROE

Exceptional 3Y Average ROE

Negative 3Y Average ROIC

-34%

ROIC is Increasing

-192% > 54%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.